An Anti-PD-1-GITR Ligand Bispecific Enhances Antitumor Immunity.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
02 05 2022
Historique:
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 4 5 2022
Statut: ppublish

Résumé

A PD-1-directed, multimeric GITR agonist enhances immune cell activation to inhibit tumor growth.

Identifiants

pubmed: 35491629
pii: 694537
doi: 10.1158/2159-8290.CD-RW2022-049
doi:

Substances chimiques

Glucocorticoid-Induced TNFR-Related Protein 0
Ligands 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

OF10

Informations de copyright

©2022 American Association for Cancer Research.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH